Clinical trial · Observational
Machine Learning Model Guided by TLS Predicts Survival and Immune Features in Gastric Cancer
TLS-Informed Machine Learning Model Predicts Survival and Immune Landscape in Locally Advanced Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop and validate a machine learning model that uses information from tertiary lymphoid structures (TLSs)-specialized immune-related cell clusters found near tumors-to predict survival outcomes and immune characteristics in patients with locally advanced gastric cancer. By analyzing clinical data, pathology, and imaging results, the model may help doctors better understand a patient's prognosis and personalize treatment strategies. The study will also explore how TLS-related immune patterns relate to the effectiveness of certain therapies, potentially offering new insights for immune-based treatment planning.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Tertiary Lymphoid Structures (TLS) | — | UNRESOLVED | — |
| Tumor Immune Microenvironment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TLS-Informed Machine Learning Prognostic Model | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Locally Advanced Gastric Cancer Patients
- interventionNames
- Other: TLS-Informed Machine Learning Prognostic Model
Primary outcomes (1)
- measure
- Overall Survival Predicted by TLS-Informed Machine Learning Model
- timeFrame
- Up to 5 Years Post-Surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Histologically confirmed locally advanced gastric adenocarcinoma (clinical stage cT2-T4 and/or N+) Underwent curative-intent gastrectomy (with or without neoadjuvant therapy) Availability of adequate tumor tissue specimens for TLS assessment via digital pathology Complete baseline clinical, pathological, and follow-up data Age ≥ 18 years Written informed consent provided (if prospective study component is included) Exclusion Criteria: Distant metastases at the time of diagnosis or surgery (M1 stage) Prior history of other malignancies within the past 5 years, except for adequately treated in situ carcinoma or non-melanoma skin cancer Incomplete or missing essential clinical, pathological, or survival data Poor-quality tissue samples not suitable for TLS quantification or digital analysis Participation in another clinical trial that may interfere with the study outcomes
References
Publications (0)
Data not yet available